Day: August 12, 2022

Unveiled a new preclinical program focused on developing iPSC derived gamma-delta T cells and presented early findings at the ASGCT Annual Meeting. Presented data from Phase 1 clinical trial of INB-200 in patients with newly diagnosed GBM showing five of six fully dosed patients exceeded both median and expected progression free survival (PFS), with a sixth patient early in follow up; two patients have exceeded overall survival (OS) benchmarks established by Stupp et al, 2005 to-date. Continued to demonstrate durable morphologic complete responses from INB-100 Phase 1 clinical trial in leukemia patients with two of three patients relapse free at two years to date and all three relapse free past one year. Appointed seasoned executives to the roles of Senior Vice President, Business Development, Vice President, Regulatory Affairs, and Vice...

Demonstrates Strong Execution Despite Challenging Macroeconomic Environment and Unfavorable e-Commerce Traffic in Q2 Provides Full Year 2022 Revenue Guidance Range of $81 million to $90 million REDMOND, Wash., Aug. 12, 2022 (GLOBE NEWSWIRE) — Hour Loop, Inc. (NASDAQ: HOUR) (“Hour Loop”), a leading online retailer, announces its financial and operational results for the second quarter ended June 30, 2022. Financial Highlights for Second Quarter 2022:Total revenues increased 27.1% and 19.8% to $14.8 million, compared to $11.6 million in the year-ago period and $12.4 million for the first quarter of 2022, respectively. Net loss totaled $0.31 million, compared to net income of $1.1 million in the year-ago period and net loss of $0.65 million for the first quarter of 2022. Cash used in operating activities for the six months ended...

Conference Call Friday August 12, 2022 at 4:30 p.m. ET SAN DIEGO, Aug. 12, 2022 (GLOBE NEWSWIRE) — Beam Global, (Nasdaq: BEEM, BEEMW), (the “Company”), the leading provider of innovative sustainable products and technologies for electric vehicle (EV) charging, energy storage, energy security and outdoor media, today announced the financial results for the second fiscal quarter ended June 30, 2022. Fiscal Q2 2022 and Recent Company HighlightsGenerated the highest second quarter revenue in the company’s history of $3.7 million, a 75% increase over Q2 2021 Generated highest first half revenue in the company’s history of 7.5M, a 114% increase over first half 2021 Improved Gross Profitability in first half by 4% of revenue despite inflation Reduced net loss by over 14% of revenue in first half despite inflation and acquisition Grew...

LOS ANGELES, Aug. 12, 2022 (GLOBE NEWSWIRE) — Nova LifeStyle, Inc. (NASDAQ: NVFY) (“Nova LifeStyle” or the “Company”) today announced its financial results for the second quarter ended June 30, 2022. Key Financial Highlights: Operating Results for the Three Months Ended June 30, 2022Net sales for three months ended June 30, 2022 were $3.8 million, an increase of 7% from $3.5 million in the same period of 2021. Gross loss was ($3.5 million), compared to ($4 million) in the same period of 2021. Net loss was ($5.7 million), compared to ($6.3 million) loss in the same period of 2021.Operating Results for the Six Months Ended June 30, 2022Net sales for the six months ended June 30, 2022 were $7.5 million, an increase of 9% from $6.9 million in the same period 2021. Gross (loss) was ($2.0 million), compared to ($2.6 million) in...

– Positive Data from the Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia (ET) Presented at European Hematology Association (EHA) Meeting 2022 – – Positive Data from the Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis Presented at EHA 2022 – – First Participant Dosed in Investigator-Sponsored Phase 1/2 Study of Bomedemstat in Combination with Atezolizumab in Small Cell Lung Cancer – – Obtained Advice from FDA Clinical Outcomes Assessment (COA) Group with Regard to Patient Reported Outcome (PRO) Endpoints for the Company’s Planned Phase 3 Trial of Bomedemstat in ET Patients – SOUTH SAN FRANCISCO, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) — Imago BioSciences, Inc. (“Imago” or the “Company”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering...

First patient dosed in a sponsored trial of JSP191 conditioning in patients with Fanconi Anemia On schedule to initiate a registrational study in AML in the first quarter of 2023 On schedule to initiate a new study of JSP191 as a therapeutic in second-line therapy for lower-risk, transplant ineligible MDS patients later this yearREDWOOD CITY, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company focused on developing multiple new therapies for the field of stem and cellular medicine, today announced second quarter 2022 financial results and provided a corporate update. “During our second quarter, we continued to advance multiple clinical programs for our anti-CD117 monoclonal antibody, JSP191, announcing the first patient enrolled in a trial in Fanconi Anemia, advancing...

KING OF PRUSSIA, Pa., Aug. 12, 2022 (GLOBE NEWSWIRE) — Nocopi Technologies, Inc. (OTC Pink: NNUP), a developer of specialty reactive inks used in entertainment, toy and educational products as well as in document and product authentication technologies to combat fraud, today announced results for its second quarter ended June 30, 2022 (Q2 ’22). Nocopi’s SEC filings are available here. Q2’22 ResultsQ2’22 revenue increased to $514,300 as compared to Q2’21 revenue of $513,900, principally reflecting an increase in license and royalty revenue offset by a decrease in specialty ink purchases by Asia-based printers. Demand for Nocopi’s specialty ink offerings continues to be impacted by global supply chain challenges, including significant increases in international shipping costs, congestion at Chinese ports, as well as pandemic-related...